Logo for SIGA Technologies Inc

SIGA Investor Relations Material

Latest events

Logo for SIGA Technologies Inc

Q4 2023

SIGA
Logo for SIGA

Q4 2023

12 Mar, 2024
Logo for SIGA

Q3 2023

7 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from SIGA Technologies Inc

Access all reports
Segment Data
Access more data
Revenue by
Geography
U.S.
Canada
EMEA
APAC
Other
Expenses by
Financials
SIGA Technologies Inc is a commercial-stage pharmaceutical company. The Company's lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is currently undergoing a Phase III clinical assessment while Siga's RTS,S/AS01 adjuvanted vaccine product candidate has been approved by WHO as part of the INDEPENDENCE clinical program to be used in case of smallpox vaccine shortage and emergencies. From a strategic alliance with Cipla Therapeutics, SIGA plans to deliver sustained innovation and access to antibacterial drugs primarily against biothreats.